Ahvie Herskowitz: Therapeutic Plasma Exchange as a Precision Cancer Weapon
Ahvie Herskowitz, Founder and Medical Director at Anatara Medicine, President at American College for Advancement in Medicine, shared a post on LinkedIn:
“Therapeutic Plasma Exchange (TPE) as a precision cancer weapon
A question I’ve been exploring in-depth over recent years: if the plasma itself is carrying oncogenic signaling molecules – tumor-derived exosomes, soluble PD-L1, senescence-associated secretory phenotypes, pro-inflammatory cytokines – can we intervene at the level of the blood’s liquid component and meaningfully shift the tumor microenvironment?
Therapeutic plasma exchange (TPE) has been used for decades in autoimmune conditions like thrombotic thrombocytopenic purpura, Guillain-Barré syndrome, and myasthenia gravis.
In recent studies, and what I presented at the Advanced Applications in Medical Practice (AAMP) conference this past fall, is the application of TPE in advanced cancer – specifically to strip the plasma of molecules that facilitate immune evasion and tumor proliferation.
The mechanism is more precise than people realize.
We’re not simply ‘cleaning the blood.’
We’re removing soluble PD-L1 and PD-L1-positive extracellular vesicles – the very molecules that inhibit programmed cell death in tumor cells.
Research published by Orme in 2020 documented that TPE clears these circulating checkpoints, and our clinical data has shown corresponding biomarker shifts that are difficult to dismiss: CRP reductions exceeding 90%, ferritin drops of nearly 90%, and complement cascade markers like C4a falling by over 80% in individual cases.
Those numbers represent a fundamental alteration of the inflammatory and immunosuppressive terrain in which advanced cancers operate.
The plasma carries everything – the good and the harmful.
Oncogenes, tumor-derived exosomes, autoantibodies, heavy metals, forever chemicals, and plastics.
When you exchange that plasma with ‘clean’ albumin, you’re essentially resetting the immunological landscape and giving the body’s surveillance systems a clearer field of operation.
This is terrain medicine applied at the molecular level. It’s not replacing conventional oncologic treatment – it’s addressing the environment in which those treatments either succeed or fail.
The TPE method we use at Anatara Medicine has been patented and published in placebo-controlled trials that show a reduction in circulating PD-L1 and PDL-1-positive inhibitors and its reversing effects for cognitive decline.
I believe TPE will become a standard adjunctive modality in integrative oncology within the next decade.
Right now, very few clinics are applying it in this context.
For colleagues in integrative and functional medicine: what’s your experience been with plasma-level interventions in complex cases?
Stay updated with Hemostasis Today.
-
Apr 2, 2026, 13:51Clare Woodford: New NHS Access to Semaglutide Offers Hope to Prevent Another Stroke or Heart Attack
-
Apr 2, 2026, 13:46Ney Carter Borges: Plaque Erosion Defines a Distinct Mechanistic and Clinical Phenotype in Acute Coronary Syndrome
-
Apr 2, 2026, 13:19John Michael Quinn: Prehospital Whole Blood Remains Critical in Trauma Care
-
Apr 2, 2026, 13:04Dario Bongiovanni: ESC Working Group on Thrombosis Consensus Document Is Now Live
-
Apr 2, 2026, 12:52Ashfa Anwar: While The World Is Editing Genes, Sri Lanka Is Still Thawing Plasma for Hemophilia
-
Apr 2, 2026, 11:48Piotr F. Czempik: Effect of Uremia on Platelet-Mediated Clot Strength in Sepsis
-
Apr 2, 2026, 08:22Chokri Ben Lamine: Laboratory Findings and Management of Severe Type 3 von Willebrand Disease
-
Apr 2, 2026, 08:12Heghine Khachatryan: Dementia at the Intersection of Hematology and Hemostasis
-
Apr 2, 2026, 08:03Thomas Pincez: Revised Guidelines Improve Care for Pediatric Immune Thrombocytopenia